Medical isotope production facility
SHINE Medical Technologies is constructing a medical isotope production facility at Janesville, Wisconsin, US.
The company submitted a construction permit application for the plant to the US Nuclear Regulatory Commission (NRC) in 2013, which included environmental and preliminary safety reports. The NRC approved construction in February 2016.
SHINE will use the facility to produce molybdenum-99 and other medical isotopes used in medical imaging procedures.
A ground-breaking ceremony was held in May 2019 for construction of the medical isotope production facility.
Molybdenum-99 (moly-99) is a radioisotope used in medical diagnostic procedures.
Most nuclear reactors producing moly-99 will be closed over the next few years. These ageing reactors have led to isotope shortages, impacting patient care.
The US accounts for approximately 50% of the demand for moly-99. However, it depends on imports from foreign nuclear reactors. SHINE aims to produce cost-effective and environment-friendly medical isotopes domestically in the US without using highly-enriched uranium (HEU) to reduce the country’s reliance on trade.
The facility will consist of five buildings covering a total area of 91,000ft². It will include the main production facility equipped with eight sub-critical irradiation units and a radioisotope production facility with three hot cells for moly-99 separation and purification.
The facility will also include waste staging and shipping capabilities, an administrative building, a diesel generator and other ancillary infrastructures such as storage sheds, storage tanks, parking lots and water tanks.
Construction of Building One of the medical isotope production facility commenced in August 2017 and was completed in February 2018.
The 11,400ft² building accommodates an integrated, full-size SHINE production system, which will be used to train employees while the main production facility is being constructed.
Building One will also be used as a technology development centre once the main building is completed.
SHINE will deploy a patented non-reactor-based technology developed in partnership with Argonne National Laboratory and GE Healthcare in November 2015 at the facility.
The technology uses a sub-critical fission process in irradiation units to manufacture medical radioisotopes. The main components of the irradiation units include a neutron driver, a sub-critical operating assembly, a light-water pool and surrounding biological shielding.
Deuterium ion source contained in the neutron driver is accelerated into a tritium gas target chamber to produce neutrons, which fire upon a target solution contained in the sub-critical operating assembly to produce radioisotopes.
The light-water pool provides shielding for the target solution and also acts as a neutron reflector.
The process is cost-effective, uses less electricity and produces less waste.
The Janesville facility will primarily produce moly-99 radioisotope to generate technetium-99m (tech-99m), which is used in more than 40 million medical imaging procedures a year.
Tech-99m is used to conduct stress tests to diagnose heart disease and bone scans to determine the stage of cancer progression.
The facility will also produce cancer therapy iodine-131 and xenon-133, used to diagnose lung disease.
Baker Concrete Construction was contracted for the construction of the medical isotope production facility in September 2017.
Construction of Building One was executed by JP Cullen.
SHINE Medical Technologies was established in 2010 with a focus on the production of radioisotopes for medicine purposes, headquartered in Janesville, Wisconsin, US.
The company entered moly-99 supply agreements with GE Healthcare and Lantheus Medical Imaging in 2014.
SHINE is also evaluating potential sites for the development of a second facility to serve the Asia and Middle Eastern markets.
The Columbus Innovation District is a proposed healthcare and technology hub within the Ohio State University in the state of…
Rocket Pharmaceuticals will build a new research and development (R&D) and manufacturing facility in Cranbury, New Jersey, US to support…
BioNTech’s manufacturing site in Marburg, Germany, will be used for the production of its Covid-19 vaccine candidate, BNT162. Based on…